Drug search by name

Vitrakvi (Larotrectinib Capsules) and Hepatotoxicity/liver impairment

Result of checking the interaction of drug Vitrakvi (Larotrectinib Capsules) and disease Hepatotoxicity/liver impairment for safety when used together.

Check result:

Vitrakvi (Larotrectinib Capsules) <> Hepatotoxicity/liver impairment

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Forty- five percent of the patients receiving larotrectinib had increased hepatic parameters, including Grade 3 increased AST or ALT in 6% of patients. Monitor liver tests, including ALT and AST, every 2 weeks during the first month of treatment, then monthly thereafter, and as clinically indicated. Treatment should be withheld or permanently discontinued based on the severity of hepatic toxicity. Caution is advised in patients with moderate to severe hepatic impairment as the drug clearance was reduced in these patients (Child-Pugh B and C). Dose should be reduced on these patients as recommended by the manufacturers (refer to prescribing information).

Vitrakvi (Larotrectinib Capsules)

Generic Name: larotrectinib

Brand Name: Vitrakvi

Synonyms: Vitrakvi

What is Vitrakvi (Larotrectinib Capsules)?